Nauka i natura

An outbreak of pneumonia caused by an unknown virus occurred in Wuhan, China in December of 2019. The pathogen was soon identified to be a novel coronavirus, SARS-CoV-2, named by International Committee on Taxonomy of Viruses (ICTV). Previous researches indicated that by introducing negatively and positively charged amino acids Glu (E) and Lys (K), EK1 peptide can potently inhibits multiple CoV cell-cell fusion and blocks various pseudotyped and live CoV infection. Creative Biolabs offers a range of bio-pharmaceutical products. We provide EK1 fusion peptide development services to help you for SARS-CoV-2 researches and treatments and other CoV diseases, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS). ek1 peptide sars
https://sars-cov-2.creative-biolabs.com/fusion-peptide-ek1-for-sars-cov-2-treatment.htm